Listen to the article
0:00
0:00
Kernaussagen
🌐 Translate Article
Translating...
📖 Read Along
💬 AI Assistant
🤖
Hi! I'm here to help you understand this article. Ask me anything about the content!
CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced the following update from President and Chief Executive Officer, Dror Bashan, to its stockholders.
Dear Protalix Stockholders,
As we look forward to 2026, we remain focused on building with our partners a growing, profitable business and an innovative pipeline for patients with high-need rare diseases.
Den vollständigen Artikel hier lesen
